Review Article
Role of miRNAs in prostate cancer: Do we really know everything?

https://doi.org/10.1016/j.urolonc.2020.03.007Get rights and content

Highlights

  • MiRNAs are involved in key steps of prostate cancer development and progression.

  • MiRNAs act as oncogenic or oncosuppressor factor in cancerogenesis.

  • MiRNAs as potential biomarkers for diagnosis and prognosis of prostate cancer.

  • MiRNAs could play a relevant role in targeted therapy.

Abstracts

Many different genetic alterations, as well as complex epigenetic interactions, are the basis of the genesis and progression of prostate cancer (CaP). This is the reason why until now the molecular pathways related to development of this cancer were only partly known, and even less those that determine aggressive or indolent tumour behaviour. MicroRNAs (miRNAs) represent a class of about 22 nucleotides long, small non-coding RNAs, which are involved in gene expression regulation at the post-transcriptional level. MiRNAs play a crucial role in regulating several biological functions and preserving homeostasis, as they carry out a wide modulatory activity on various molecular signalling pathways. MiRNA genes are placed in cancer-related genomic regions or in fragile sites, and they have been proven to be involved in the main steps of carcinogenesis as oncogenes or oncosuppressors in many types of cancer, including CaP. We performed a narrative review to describe the relationship between miRNAs and the crucial steps of development and progression of CaP. The aims of this study were to improve the knowledge regarding the mechanisms underlying miRNA expression and their target genes, and to contribute to understanding the relationship between miRNA expression profiles and CaP.

Introduction

Prostate cancer (CaP) is the most common male malignancy worldwide, with a prevalence of over 3.6 million and an estimated 174,650 new cases in 2019 in the USA [1,2]. CaP affects about 30% of men aged over 50 years old, but only 10% of them will be diagnosed with clinically significant disease [3]. The definitive` diagnosis of CaP is based on prostate biopsy that has to be performed when an altered PSA level and/or a suspicious Digital Rectal Examination (DRE) are detected. The main goals in CaP diagnosis are to detect cancer at an early stage and to distinguish the clinically significant disease from the indolent one in order to treat more cancer patients at an initial and localized stage, improve cure rates, and to avoid overtreatment [4]. However, the main problem with the diagnostic management of CaP is the poor accuracy of currently available tools. The positive predictive power of prostate biopsy performed for serum PSA levels greater than 2.5 to 4 ng/ml and/or abnormalities in DRE is about 24% to 37% [5], [6], [7]. Although the introduction of serum PSA evaluation in clinical practice has dramatically improved the early diagnosis and consequently the success rate of confined-organ disease treatment, its extensive use is not recommended. In fact, PSA is an organ-specific, rather than a cancer-specific, marker and, for this reason, altered PSA levels may be due to benign conditions as well as cancer. This poor specificity of PSA has brought about an increase in unnecessary biopsies and diagnoses of indolent tumours that are not life-threatening [8]. Moreover, the overtreatment of indolent disease could expose the patients to possible complications without any benefit in terms of cancer-specific survival. Albertsen et al. demonstrated that the risk of dying from a Gleason Score of 8 to 10 CaP within 10 years is about 12.1%, while this risk is minimal for low-risk disease [9]. Many different genetic alterations, as well as complex epigenetic interactions, are at the basis of the genesis and progression of CaP [10]. For these reasons, until now the molecular pathways related to the development of this cancer, and those determining aggressive or indolent tumour behaviour, were still unknown. In the last decades, basic research has been focused on the discovery of new biomarkers able both to provide an accurate and early diagnosis, and to distinguish aggressive forms from indolent ones in order to plan an individualized therapy [11].

MicroRNAs (miRNA) are short noncoding single-stranded RNA molecules, that regulate post-transcriptional gene expression by complementary binding to the 3′ untranslated region (3’-UTR) of mRNAs, which, in turn, lead to translational suppression or degradation of the mRNA target [12] (Fig. 1). MiRNAs play a crucial role in regulating several biological functions and preserving homeostasis as they carry out a wide modulatory activity on various molecular signalling pathways. About 60% of all human genes are regulated by miRNAs [13].

Because miRNAs are placed in cancer-related genomic regions or in fragile sites, and are involved in main steps of carcinogenesis since they can regulate the expression of many oncogenes and oncosuppressor genes, miRNAs have been assessed as potential biomarkers for almost every type of cancer [14,15]. In 2007, for the first time, Porkka et al. associated a particular miRNA expression profile with CaP [16].

The evidence of their key role in prostate carcinogenesis and progression, their stability in biological fluids such as serum and urine, and their resistance to various storage conditions make miRNAs promising candidates as minimally invasive diagnostic and prognostic biomarkers for CaP [17].

We performed a narrative review to describe the relationship between miRNAs and the crucial steps of CaP development and progression. The aim of this study was to improve the knowledge concerning the mechanisms underlying miRNA expression and their target genes in CaP. (Fig. 2).

Section snippets

MiRNAs biogenesis and function

Canonical miRNAs biosynthesis begins in the nucleus with the transcription of long primary transcripts, called primary-miR (pri-miR), by RNA Polymerase II/III [18]. These primary transcripts are characterized by stem-loop structures (a 3’ poly-A-tail and 5’ methylated cap) and can be up to several hundred nucleotides long. Pri-miRs are then processed by the Microprocessor complex that is composed of Drosha (an RNase III endonuclease) and DGCR-8 (DiGeorge syndrome chromosomal or critical region

Cell cycle

Aberrant cell cycle regulation is a hallmark of carcinogenesis [28] often correlated with dysfunction of the miRNAs that control the expression of cell cycle-related genes.

Some miRNA functions are already established: miR-193a-3p is known to be a tumour suppressor and is expressed less in cancerous tissues compared to Benign Prostatic Hyperplasia (BPH). A recent study demonstrates that in gain-of-function experiments, miR-193a-3p can inhibit cell growth by regulating CCND1 and promoting

Proliferation

MiRNAs have been described as being implicated in CaP cell proliferation, causing malignant development and progression. Generally, the role of miRNAs in cell proliferation of CaP was studied in prostatic tissues and/or in the prostatic cancer cell line.

In order to understand the role of miRNAs in tumour prostatic proliferation, Aakula et al. tested hundreds of miRNAs by in vitro functional assays in CaP cell lines, proving that 14 miRNAs were implicated in cell proliferation. These miRNAs were

Apoptosis

Apoptosis is a physiological form of cell death required for the removal of cells that are damaged, aged, or transformed. The mechanisms underlying apoptosis are, therefore, complex and involve many signalling pathways. In recent decades, the role of miRNAs has been studied in cancerous and healthy prostate cells or tissues, and it was observed that in both conditions some miRNAs regulate the apoptosis pathway.

Indeed, in CaP cells, miR-34a, miR-34c, miR-15a, and miR-204-5p were identified as

Epithelial mesenchymal transition

Epithelial Mesenchymal Transition (EMT) is a physiological process by which epithelial cells acquire a mesenchymal phenotype. A dysregulation of EMT is one of the key processes underlying metastatic CaP. E-cadherins are cell surface proteins designated to establish and maintain cell-cell interactions, and they are regarded as gatekeepers of the epithelial state. In CaP, it has been proved that aberrant activation of EMT is associated with lost, or reduced, expression of E-cadherins by

Metastasis

The metastasis process includes several phases that make cancer prostatic cells able to degrade the extracellular matrix (ECM), violate host tissue and invade the lymphatic and blood systems (intravasal time). Circulating tumour cells survive until they reach the metastatic site, where they leave the bloodstream (extravasal time), colonize the foreign microenvironment and begin proliferation to generate a secondary tumour [105,106]. Of millions of tumour cells that infiltrate the bloodstream,

Future perspectives

In recent years, several studies have indicated that miRNAs circulate in different biological fluids, including blood, urine and semen, and that they are detectable in cell culture media, which is useful for in vitro analysis [123]. Moreover, they could be carried with lipoproteins, encapsulated into microparticles (exosome‐like and apoptotic bodies), or linked to Argonaute proteins [124]. Circulating miRNAs, therefore, offer the potential of being utilised as non-invasive biomarkers for

Conclusion

MiRNAs represent a class of small, non-coding RNAs regulating gene expression at the post-transcriptional level. They regulate many biological functions through a wide modulatory activity on various molecular signalling pathways, and their dysregulation has been proved to be involved in carcinogenesis and the progression of CaP. Many studies have suggested that miRNAs may be promising non-invasive biomarkers in CaP, but no miRNA has yet been used as biomarker for diagnosis or prognosis of CaP

References (132)

  • D Wang et al.

    MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway

    Biomed Pharmacother

    (2018)
  • S Zhang et al.

    miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA

    Exp Therapeut Med

    (2018)
  • Y-C Lin et al.

    Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells

    Asian J Surg

    (2017)
  • J Yang et al.

    RLIP76-dependent suppression of PI3K/AKT/Bcl-2 pathway by miR-101 induces apoptosis in prostate cancer

    Biochem Biophys Res Commun

    (2015)
  • X-H Chen et al.

    TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells

    Mol Immunol

    (2015)
  • KH Cho et al.

    STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion

    Cancer Lett

    (2013)
  • MN Tran et al.

    The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells

    J Biol Chem

    (2013)
  • M Puhr et al.

    Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205

    Am J Pathol

    (2012)
  • R el Bezawy et al.

    miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis

    Cancer Lett

    (2017)
  • Z Culig

    Epithelial mesenchymal transition and resistance in endocrine-related cancers

    Biochimica et Biophysica Acta (BBA) - Mol Cell Res

    (2019)
  • R Tedja et al.

    Protein kinase C–mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it

    J Biol Chem

    (2019)
  • B Yang et al.

    Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5

    Biomed Pharmacother

    (2019)
  • J Zhang et al.

    Metformin inhibits epithelial–mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4

    Biochem Biophys Res Commun

    (2014)
  • J Ferlay et al.

    Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

    Int J Cancer

    (2019)
  • KD Miller et al.

    Cancer treatment and survivorship statistics, 2019

    CA Cancer J Clin

    (2019)
  • L Wang et al.

    Gene Networks and microRNAs implicated in aggressive prostate cancer

    Cancer Res

    (2009)
  • MG Egidi et al.

    Stability assessment of candidate reference genes in urine sediment of prostate cancer patients for miRNA applications

    Dis Markers

    (2015)
  • IM Thompson et al.

    Assessing prostate cancer risk: results from the prostate cancer prevention trial

    J Natl Cancer Inst

    (2006)
  • G Cochetti et al.

    Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

    Onco Targets Therapy

    (2016)
  • E Mearini et al.

    The combination of urine DD3 (PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer

    Biomarkers

    (2009)
  • PC Albertsen

    20-year outcomes following conservative management of clinically localized prostate cancer

    JAMA

    (2005)
  • C Antognelli et al.

    Glyoxalase 1−419C>A variant is associated with oxidative stress: implications in prostate cancer progression

    PLoS One

    (2013)
  • VN Talesa et al.

    Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers

    Cancer Biomarkers

    (2009)
  • RC Friedman et al.

    Most mammalian mRNAs are conserved targets of microRNAs

    Genome Res

    (2008)
  • GA Calin et al.

    Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers

    Proc Natl Acad Sci

    (2004)
  • P Pastina et al.

    Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

    J Thoracic Disease

    (2017)
  • KP Porkka et al.

    MicroRNA expression profiling in prostate cancer

    Cancer Res

    (2007)
  • G Guelfi et al.

    Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research

    Sci Rep

    (2018)
  • M Ha et al.

    Regulation of microRNA biogenesis

    Nat Rev Mol Cell Biol

    (2014)
  • AM Denli et al.

    Processing of primary microRNAs by the microprocessor complex

    Nature

    (2004)
  • J Han et al.

    The Drosha-DGCR8 complex in primary microRNA processing

    Genes Dev

    (2004)
  • C Okada et al.

    A high-resolution structure of the pre-microRNA nuclear export machinery

    Science

    (2009)
  • J-J Song

    Crystal structure of argonaute and its implications for RISC slicer activity

    Science

    (2004)
  • SL Ameres et al.

    Diversifying microRNA sequence and function

    Nat Rev Mol Cell Biol

    (2013)
  • Y Liu et al.

    MicroRNA-193a-3p inhibits cell proliferation in prostate cancer by targeting cyclin D1

    Oncol Lett

    (2017)
  • M Wang et al.

    MicroRNA‐487a‐3p functions as a new tumor suppressor in prostate cancer by targeting CCND1

    J Cell Physiol

    (2020)
  • RK Nam et al.

    MicroRNA‐139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL

    Prostate

    (2019)
  • G-M Zhang et al.

    MicroRNA-302a suppresses tumor cell proliferation by inhibiting AKT in prostate cancer

    PLoS One

    (2015)
  • Y Bao et al.

    MiR-96 expression in prostate cancer and its effect on the target gene regulation

    Eur Rev Med Pharmacol Sci

    (2017)
  • Y Hao et al.

    Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo

    Cancer Prev Res

    (2011)
  • Cited by (33)

    View all citing articles on Scopus
    View full text